Drug Profile
Research programme: cardiovascular disease therapy - Resverlogix
Alternative Names: RVX-408Latest Information Update: 16 Jan 2015
Price :
$50
*
At a glance
- Originator Resverlogix Corporation
- Class Small molecules
- Mechanism of Action Apolipoprotein A I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 01 Jan 2015 No development reported - Preclinical for Cardiovascular disorders in USA (PO)
- 19 Jan 2011 Preclinical development is ongoing in USA
- 10 Dec 2007 The US FDA grants approval to Resverlogix to begin a phase I clinical trial for RVX 208